Pathogenic cells and mediators involved in chronic inflammatory skin diseases

Pathogenic cells and mediators involved in chronic inflammatory skin diseases - Pathogenic cells in inflammatory skin diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49586

Enrollment

500

Registered

2020-07-16

Start date

2021-02-23

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammatory dermatitis longlasting skin inflammation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult (age >=18) patients with inflammatory skin disorders: psoriasis, atopic dermatitis, lichen planus, or (irritant, allergic, or photo) contact dermatitis

Exclusion criteria

Exclusion criteria: Patients with hypertrophic scars, with keloid, with a history of hypersensitivity or allergy to local anesthesia, and patients with hemophilia or other clotting disorders.

Design outcomes

Primary

Measure	Time frame
1. To identify the key pathogenic cells, their function, interaction and production of mediators (e.g. cytokines, chemokines) in inflammatory skin diseases and to recognize the role of these parameters in the etiopathology and to what extent they are specific for the different disorders. 2. To assess if the identified putative pathogenic cells are also present in asymptomatic skin of the same patient (or persist after therapy) or in healthy normal human skin. If so, the question needs to be answered why these cells are only locally triggered to cause the disease (e.g. higher quantity of pathogenic cells, presence of activation factors). 3. To assess if the presence of identified putative pathogenic cells and mediators correlate with therapy (do they decline in responders and persist in non-responders), and determine whether different treatment modalities have differential potential to change the frequency and functional state of those pathogenic cells and mediators. 4. To identify key disease-specific biomarkers (genetic and protein level) in blood or skin samples that can accurately predict disease progression or therapeutic response at an early stage and independent of the therapy modality used.	—

Measure

Time frame

1. To identify the key pathogenic cells, their function, interaction and production of mediators (e.g. cytokines, chemokines) in inflammatory skin diseases and to recognize the role of these parameters in the etiopathology and to what extent they are specific for the different disorders. 2. To assess if the identified putative pathogenic cells are also present in asymptomatic skin of the same patient (or persist after therapy) or in healthy normal human skin. If so, the question needs to be answered why these cells are only locally triggered to cause the disease (e.g. higher quantity of pathogenic cells, presence of activation factors). 3. To assess if the presence of identified putative pathogenic cells and mediators correlate with therapy (do they decline in responders and persist in non-responders), and determine whether different treatment modalities have differential potential to change the frequency and functional state of those pathogenic cells and mediators. 4. To identify key disease-specific biomarkers (genetic and protein level) in blood or skin samples that can accurately predict disease progression or therapeutic response at an early stage and independent of the therapy modality used.

—

Countries

Netherlands

Outcome results